Purchase this article with an account.
Sudeshna Sil Kar, Duriye Damla Sevji, Vincent Dong, Sunil K. Srivastava, Anant Madabhushi, Justis P. Ehlers; Multi-Compartment OCT-derived Radiomics Features to predict Anti-VEGF Treatment Durability for Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2021;62(11):3.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
There are currently no established predictors for therapeutic durability of anti-VEGF therapy for diabetic macular edema (DME) and retinal vein occlusion (RVO) secondary to retinal vascular diseases. The main objective of this study was to identify the (i) texture- based radiomics features within individual fluid and retinal tissue compartments of the baseline optical coherence tomography (OCT) images associated with anti-VEGF treatment response and (ii) the specific spatial (fluid and/or retinal tissue) compartments that contribute the most pertinent features for predicting therapeutic response.
A total of 962 texture-based radiomic features were extracted from each of the fluid and retinal tissue compartments from the baseline OCT images, obtained from the PERMEATE clinical trial. PERMEATE is a prospective open-label IRB- approved study for the treatment of naïve eyes with DME and RVO using intravitreal aflibercept injection (IAI) to evaluate imaging biomarkers and treatment response. The two top-performing features were selected from the consensus of different feature selection methods and were evaluated in conjunction with four different machine learning classifiers: Linear Discriminant Analysis (LDA), Quadratic Discriminant Analysis (QDA), Random Forest (RF), and Support Vector Machine (SVM) in a 3-fold cross-validated approach to distinguish the eyes tolerating extended interval dosing (Non-rebounders) and those requiring more frequent dosing (Rebounders).
In this study, we found that the Laws textural features from within the intraretinal fluid (IRF) subcompartment were most strongly associated with the likelihood of a patient being a rebounder or a non-rebounder. A combination of fluid and retinal tissue features yielded a cross-validated area under the receiver operating characteristic curve (AUC) of 0.78±0.08 in distinguishing rebounders from non-rebounders via 3-fold cross validation on the PERMEATE study.
Our study revealed that the texture-based radiomics features pertaining to the IRF subcompartment were most discriminating between rebounders and non-rebounders to anti-VEGF therapy for macular edema in retinal vascular disease. With further validation, OCT-based imaging biomarkers may have potential for facilitating personalized therapeutic guidance.
This is a 2021 Imaging in the Eye Conference abstract.
This PDF is available to Subscribers Only